Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 AND SODIUM CHLORIDE 0 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 AND SODIUM CHLORIDE 0 9.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions essential for nerve impulse transmission, muscle contraction, and acid-base balance. Sodium chloride provides sodium ions, which are critical for maintaining extracellular fluid volume, osmotic pressure, and electrochemical gradients.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion. Potassium chloride 0.3% (3 g/L) and sodium chloride 0.9%: administer at a rate not exceeding 10 mmol/h (0.75 g/h) of potassium, maximum 200 mmol (15 g) per 24 hours. Dose adjusted based on serum potassium and clinical status.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable as potassium and sodium are endogenous ions; distribution and elimination are rapid and depend on renal function and total body stores.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Potassium: Approximately 90% renal excretion, 10% fecal. Sodium: Excreted renally, >90% under normal conditions.
Category C
Category A/B
Electrolyte
Electrolyte